|Day Low/High||0.06 / 0.06|
|52 Wk Low/High||0.04 / 3.46|
Stocks close mixed even after strong December jobs report; Europe worries weigh on the market
Cramer says job growth can counter the tough financial crisis in Europe.
Cramer says the stock will benefit from the short squeeze.
These stories made today's top 10 list of articles and videos on TheStreet.
Dendreon surprises with better-than-expected sales of its prostate cancer therapy Provenge in the December quarter.
Dendreon Corporation (Nasdaq: DNDN) today announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million.
Gilead Sciences is loved, Amgen is hated and new drug launches will continue to struggle, say Wall Street's biotech investing pros.
Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the 29th Annual J.
What every biotech investor needs to know before next week's J.P. Morgan Healthcare Conference.
There were plenty of examples of management hubris and poor judgment among Wall Street's movers and shakers that destroyed stock value this year.
Some Wall Street movers and shakers manage to destroy stocks purely through hubris.
TheStreet's readers tagged this biotech chief executive with the 'worst' title, topping four other nominees.
Dendreon's CEO Discusses NASDAQ OMX 27th Investor Program - Earnings Call Transcript
Dendreon Corporation (NASDAQ:DNDN) today announced that it has agreed to sell for $125 million in cash its royalty interest related to intellectual property licensed to Schering-Plough Ltd.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
There have been plenty of dumb things to be thankful for lately. Here are the answers to our holiday quiz, and congrats to the winner, Richard Greene.
The five nominees for Worst Biotech CEO of 2011 face the wrath of readers; one of whom will get tagged with this dishonorable award.
Test your knowledge of Wall Street's antics over the past few months.
Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: Deutsche Bank BioFEST in Boston, Massachusetts on December 5, 2011 at 9:30 am ET ...
Dendreon Corporation (NASDAQ:DNDN) today announced the Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of ...
TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.
Wal-Mart's U.S. same-stores sales rise 1.3%, reversing declines. The stock is lower in premarket trading Tuesday.
SAC Capital purchased the SPDR Gold Trust ETF and industrial gas company Praxair in the third quarter.
Billionaire hedge fund manager Steven Cohen likely took a huge loss in Dendreon when the stock blew up in August.
Dendreon was a leading decliner within the health care sector, falling 6 cents (-0.8%) to $7.21 on average volume.
Optimism about the eurozone is giving U.S. futures a boost today.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.